Cannabidiol Shows Promise in the Fight Against SARS-CoV-2
A University of Chicago study, funded by the National Institutes of Health, suggests that an oral solution of cannabidiol (CBD)—derived from the cannabis plant—may be an effective antiviral agent with the potential to prevent SARS-CoV-2 infection. Researchers found that CBD hindered infection with the novel coronavirus, prohibiting replication of SARS-CoV-2 in the lungs. These effects may make CBD an effective prevention and early treatment tool in the fight against COVID-19. Researchers noted, however, that the inclusion of tetrahydrocannabinol, or THC, the part of the cannabis plant that produces a “high,” negates the antiviral properties of CBD. The study authors suggest that additional research, including well-designed clinical trials, is necessary before CBD should be included in the COVID-19 armamentarium, and that ensuring the same quality and dosage at this time is challenging due to little regulation of the over-the-counter CBD market. Click here to read more.